Drugs / Cantharidin
Cantharidin
also known as
VP-102 · Cantaridina · Cantharides camphor · Cantharidine · Cantharidinum · NSC-61805 · YCANTH
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | YCANTH | — | 2023-07-21 | fda.gov ↗ |
Trials 14
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05597098 | Dec 2022 → Dec 2027 expected | — | Queen Mary University of London | Active not recruiting | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT01762787 | Aug 2010 → Jan 2011 | — | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 25 trials · 1 met primary | ||||||
| Phase 2 | NCT03981822 | Jun 2019 → May 2020 | anogenital human papillomavirus infection, benign epithelial skin neoplasm, skin disorder caused by infection | Verrica Pharmaceuticals Inc. | Completed | Met primary |
| Phase 2 | NCT03487549 | Mar 2018 → May 2019 | common wart, human papilloma virus infection | Verrica Pharmaceuticals Inc. | Completed | No outcome recorded |
| Phase 2 | NCT03186378 | Jun 2017 → Jun 2018 | molluscum contagiosum | Verrica Pharmaceuticals Inc. | Completed | No outcome recorded |
| Phase 2 | NCT03017846 | Sep 2016 → Sep 2017 | molluscum contagiosum | Steven R Cohen | Completed | No outcome recorded |
| Phase 2 | NCT02665260 | Jul 2012 → Nov 2015 | molluscum contagiosum | Montefiore Medical Center | Completed | No outcome recorded |
| Phase 35 trials · 2 met primary | ||||||
| Phase 3 | NCT07637734 | Jun 2026 → May 2027 expected | common wart, human papilloma virus infection | Verrica Pharmaceuticals Inc. | Recruiting | No outcome recorded |
| Phase 3 | NCT07457918 | Mar 2026 → Apr 2028 expected | common wart, human papilloma virus infection | Verrica Pharmaceuticals Inc. | Recruiting | No outcome recorded |
| Phase 3 | NCT07246590 | Dec 2025 → Jun 2027 expected | common wart, human papilloma virus infection | Verrica Pharmaceuticals Inc. | Recruiting | No outcome recorded |
| Phase 3 | NCT03377790 | Mar → Nov 2018 | molluscum contagiosum | Verrica Pharmaceuticals Inc. | Completed | Met primary |
| Phase 3 | NCT03377803 | Feb → Sep 2018 | molluscum contagiosum | Verrica Pharmaceuticals Inc. | Completed | Met primary |
| Phase 41 trial | ||||||
| Phase 4 | NCT03625960 | Jun 2006 → Jun 2007 | anogenital human papillomavirus infection | Wayne State University | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT00667225 | Jan 2008 → Jun 2009 | molluscum contagiosum | University of North Carolina, Chapel Hill | Completed | No outcome recorded |
| Comparator or background therapy4 trials | ||||||
| Phase 0 | NCT01582321 Background | Mar 2012 → Dec 2016 | — | Queen Mary University of London | Completed | No outcome recorded |
| Phase 1 | NCT03306589 Background | Aug 2017 → Jan 2018 | rheumatoid arthritis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 4 | NCT05070754 Comparator | Dec 2021 → Dec 2022 | common wart, molluscum contagiosum | Medical University of South Carolina | Completed | No outcome recorded |
| — | NCT01084824 Comparator | Jun 2007 → Jun 2008 | common wart | North Idaho Dermatology | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 6
All press releases naming this drug 14 releases
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 20 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | cantharidin | “BACKGROUND: This Phase 2, open-label study evaluated the safety, efficacy, systemic exposure, and impact on quality of life (QoL) with treatment using VP-102, a drug-device...” PMID 33400412 ↗ Jan 202117“VP-102 is a drug-device combination product containing cantharidin (0.7% w/v) in a single-use shelf-stable applicator.” PMID 34515985 ↗ Sep 2021 “SOC for treatment of Molluscum Contagiosum is cantharidin.” NCT05070754 ↗ “Each applicator contains 0.45 mL of 0.7% w/v cantharidin.” NCT07246590 ↗ “Each applicator contains 0.45 mL of 0.7% w/v cantharidin.” NCT07637734 ↗ |
| Known as | Cantaridina | ChEMBL registry synonym — accepted as the source's own label CHEMBL48449 ↗ |
| Known as | Cantharides camphor | ChEMBL registry synonym — accepted as the source's own label CHEMBL48449 ↗ |
| Known as | Cantharidine | ChEMBL registry synonym — accepted as the source's own label CHEMBL48449 ↗ |
| Known as | Cantharidinum | ChEMBL registry synonym — accepted as the source's own label CHEMBL48449 ↗ |
| Known as | NSC-61805 | ChEMBL registry synonym — accepted as the source's own label CHEMBL48449 ↗ |
| Known as | VP-102 | “This is a Phase 3, double-blind, randomized, vehicle-controlled study (Study number VP-CW-301; referred to as COVE-2 \[Cantharidin and Occlusion in Verruca Epithelium\]) to...” NCT07246590 ↗1“VP-102 is drug-device combination product containing cantharidin (0.7% w/v) and has undergone Phase III clinical trials for the treatment of molluscum contagiosum (mollusc).” PMID 34976290 ↗ Oct 2021 |
| Known as | YCANTH | “This is a Phase 3, double-blind, randomized, vehicle-controlled study (Study number VP-CW-301; referred to as COVE-2 \[Cantharidin and Occlusion in Verruca Epithelium\]) to...” NCT07246590 ↗ |
| Modality | Small molecule | — CHEMBL48449 ↗ |
| Route | Topical | “Cantharidin is a topical medicine which is applied at the clinic visit.” NCT00667225 ↗ |